Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $467.2 million versus the consensus estimate of $407.73 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.